OnKure Therapeutics (OKUR) Q4 2025 earnings summary

Executive summary

• Advanced clinical pipeline with ongoing PIKture-01 trial for OKI-219 in HR+ and HER2+ metastatic breast cancer, with updated data expected in March 2026.

• Next-generation PI3Ka pan-mutant inhibitor candidate for HR+ metastatic breast cancer to be announced in March 2026.

• Strategic expansion into vascular malformations, leveraging PI3Ka biology.

Financial highlights

• Cash and cash equivalents totaled $59.1 million as of December 31, 2025.

• R&D expenses for Q4 2025 were $10.7 million, down from $14.4 million in Q4 2024.

• G&A expenses for Q4 2025 were $3.4 million, down from $4.3 million in Q4 2024.

• Net loss for Q4 2025 was $13.5 million ($0.99 per share), compared to $17.4 million ($1.37 per share) in Q4 2024.

• Net loss for full year 2025 was $59.5 million ($4.40 per share), compared to $52.7 million ($15.28 per share) in 2024.

Outlook and guidance

• Updated safety, tolerability, and clinical activity data from PIKture-01 Parts A and B expected in March 2026.

• Initial data from triplet expansion arms (Parts C and E) anticipated in 2026.

• Next-generation PI3Ka pan-mutant inhibitor candidate announcement and further program details expected in 2026.